NPS Pharmaceuticals (NASDAQ: NPSP) has initiated a Phase 2a study to evaluate the safety and tolerability of NPSP795 in adult ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE